{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:07:58Z","timestamp":1783901278628,"version":"3.55.0"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of the study was to dosimetrically compare interstitial high-dose-rate (HDR) brachytherapy (BT) and modern external beam radiotherapy modalities, as volumetric modulated arc therapy (VMAT) and stereotactic radiotherapy with Cyberknife (CK) of tumours of the tongue and floor of the mouth in terms of dose to the critical organs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>In National Institute of Oncology, Budapest, between March 2013 and August 2022 twenty patients (11 male\/9 female) with stage T1\u20133N0M0 tongue (n = 14) and floor of mouth (n = 6) tumours received postoperative radiotherapy because of close\/positive surgical margin and\/or lymphovascular and\/or perineural invasion. High-dose-rate interstitial brachytherapy applying flexible plastic catheters with a total dose of 15 \u00d7 3 Gy was used for treatment. In addition to BT plans VMAT and stereotactic CK plans were also made in all cases, using the same fractionation scheme and dose prescription. As for the organs at risk, the doses to the mandible, the ipsilateral and the contralateral salivary glands were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean volume of the planning target volume (PTV) was 12.5 cm\n                      <jats:sup>3<\/jats:sup>\n                      , 26.5 cm\n                      <jats:sup>3<\/jats:sup>\n                      and 17.5 cm\n                      <jats:sup>3<\/jats:sup>\n                      in BT, VMAT and CK techniques, respectively, due to different safety margin protocols. The dose to the mandible was the most favourable with BT, as for the salivary glands (parotid and submandibular) the CK technique resulted in the lowest dose. The highest dose to the critical organs was observed with the VMAT technique. The mean values of D\n                      <jats:sub>2cm<\/jats:sub>\n                      3 and D\n                      <jats:sub>0.1cm<\/jats:sub>\n                      3 for the critical organs were as follows for BT, VMAT and CK plans: 47.4% and 73.9%, 92.2% and 101.8%, 68.4% and 92.3% for the mandible, 4.8% and 6.7%, 7.3% and 13.8%, 2.3% and 5.1% for the ipsilateral parotid gland, 3.5% and 4.9%, 6.8% and 10.9%, 1.5% and 3.3% for the contralateral parotid gland, 7.3% and 9.4%, 9.0% and 14.3%, 3.6% and 5.6% for the contralateral submandibular gland.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present results confirm that BT, despite being an invasive technique, is dosimetrically clearly beneficial in the treatment of oral cavity tumours and is a modality worth considering when applying radiotherapy, not only as definitive treatment, but also postoperatively. The use of the CK in the head and neck region requires further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2023-0050","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T13:08:44Z","timestamp":1701695324000},"page":"516-523","source":"Crossref","is-referenced-by-count":5,"title":["Dosimetric comparison of postoperative interstitial high-dose-rate brachytherapy and modern external beam radiotherapy modalities in tongue and floor of the mouth tumours in terms of doses to critical organs"],"prefix":"10.2478","volume":"57","author":[{"given":"\u00d6rs","family":"Ferenczi","sequence":"first","affiliation":[{"name":"Centre of Radiotherapy , National Institute of Oncology , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Major","sequence":"additional","affiliation":[{"name":"Centre of Radiotherapy , National Institute of Oncology , Budapest , Hungary"},{"name":"Department of Oncology , Semmelweis University , Budapest , Hungary"},{"name":"National Tumour Biology Laboratory , National Institute of Oncology , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[{"name":"Centre of Radiotherapy , National Institute of Oncology , Budapest , Hungary"},{"name":"E\u00f6tv\u00f6s Lor\u00e1nd University , Faculty of Science , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalma","family":"B\u00e9la","sequence":"additional","affiliation":[{"name":"Centre of Radiotherapy , National Institute of Oncology , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"T\u00f3dor","sequence":"additional","affiliation":[{"name":"Centre of Radiotherapy , National Institute of Oncology , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Polg\u00e1r","sequence":"additional","affiliation":[{"name":"Centre of Radiotherapy , National Institute of Oncology , Budapest , Hungary"},{"name":"Department of Oncology , Semmelweis University , Budapest , Hungary"},{"name":"National Tumour Biology Laboratory , National Institute of Oncology , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Oral Radiology , Osaka Dental University , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botond","family":"Bukovszky","sequence":"additional","affiliation":[{"name":"Centre of Radiotherapy , National Institute of Oncology , Budapest , Hungary"},{"name":"Department of Oncology , Semmelweis University , Budapest , Hungary"},{"name":"Department of Oral Diagnostics , Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Tak\u00e1csi-Nagy","sequence":"additional","affiliation":[{"name":"Centre of Radiotherapy , National Institute of Oncology , Budapest , Hungary"},{"name":"Department of Oncology , Semmelweis University , Budapest , Hungary"},{"name":"National Tumour Biology Laboratory , National Institute of Oncology , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"2026071211422145348_j_raon-2023-0050_ref_001","doi-asserted-by":"crossref","unstructured":"Strnad V. Treatment of oral cavity and oropharyngeal cancer. Indications, technical aspects, and results of interstitial brachytherapy. Strahlenther Onkol 2004; 180: 710\u201317. doi: 10.1007\/s00066-004-9196-x","DOI":"10.1007\/s00066-004-9196-x"},{"key":"2026071211422145348_j_raon-2023-0050_ref_002","doi-asserted-by":"crossref","unstructured":"Ferenczi \u00d6, Major T, Akiyama H, Fr\u00f6hlich G, Oberna F, R\u00e9v\u00e9sz M, et al. Results of postoperative interstitial brachytherapy of resectable floor of mouth tumors. Brachytherapy 2021; 20: 376\u201382. doi: 10.1016\/j.brachy.2020.10.008","DOI":"10.1016\/j.brachy.2020.10.008"},{"key":"2026071211422145348_j_raon-2023-0050_ref_003","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs G, Martinez-Monge R, Budrukkar A, Jose Luis G, Bengt J, Vratislav S, et al. GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update \u2013 Improvement by cross sectional imaging based treatment planning and stepping source technology. Radiother Oncol 2017; 122: 248\u201354. doi: 10.1016\/j.radonc.2016.10.008","DOI":"10.1016\/j.radonc.2016.10.008"},{"key":"2026071211422145348_j_raon-2023-0050_ref_004","doi-asserted-by":"crossref","unstructured":"Chinn SB, Myers JN. Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol 2015; 33: 3269\u201376. doi: 10.1200\/JCO.2015.61.2929","DOI":"10.1200\/JCO.2015.61.2929"},{"key":"2026071211422145348_j_raon-2023-0050_ref_005","doi-asserted-by":"crossref","unstructured":"Mazeron JJ, Ardiet JM, Haie-M\u00e9der C, Kov\u00e1cs Gy, Levendag P, Peiffert D, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009; 91: 150\u20136. doi: 10.1016\/j.radonc.2009.01.005","DOI":"10.1016\/j.radonc.2009.01.005"},{"key":"2026071211422145348_j_raon-2023-0050_ref_006","doi-asserted-by":"crossref","unstructured":"Ivaldi E, Di Mario D, Paderno A, Piazza C, Bossi P, Nicola Alessandro, et al. Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2, N0-1): A review. Crit Rev Oncol Hematol 2019; 143: 67\u201375. doi: 10.1016\/j.critrevonc.2019.08.003","DOI":"10.1016\/j.critrevonc.2019.08.003"},{"key":"2026071211422145348_j_raon-2023-0050_ref_007","doi-asserted-by":"crossref","unstructured":"Potharaju M, E Raj H, Muthukumaran M, Venkataraman M, IIangovan B, Kupussam S, et al. Long-term outcome of high-dose-rate brachytherapy and perioperative brachytherapy in early mobile tongue cancer. J Contemp Brachytherapy 2018; 10: 64\u201372. PMID: 29619058","DOI":"10.5114\/jcb.2018.74139"},{"key":"2026071211422145348_j_raon-2023-0050_ref_008","doi-asserted-by":"crossref","unstructured":"Aaboubout Y, Van der Toom QM, de Ridder MAJ, Herdt MJ, Van der Steen B, Van Lanschot GC, et al. Is the depth of invasion a marker for elective neck dissection in early oral squamous cell carcinoma? Front Oncol 2021; 11: 628320. doi: 10.3389\/fonc.2021.628320","DOI":"10.3389\/fonc.2021.628320"},{"key":"2026071211422145348_j_raon-2023-0050_ref_009","unstructured":"Sternick ES, editor. The theory and practice of intensity modulated radiation therapy. 1st edition. Madison WI: Advanced Medical Publishing; 1997."},{"key":"2026071211422145348_j_raon-2023-0050_ref_010","doi-asserted-by":"crossref","unstructured":"Gr\u00e9goire V, De Neve W, Eisbruch A, Lee N, Van den Weyngaert, Van Gestel D, et al. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist 2007; 12: 555\u201364. doi: 10.1634\/theoncologist.12-5-555","DOI":"10.1634\/theoncologist.12-5-555"},{"key":"2026071211422145348_j_raon-2023-0050_ref_011","doi-asserted-by":"crossref","unstructured":"Yu CX, Li XA, Ma L, Chen D, Naqvi S, Shepard D, et al. Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys 2002; 53: 453\u201363. doi: 10.1016\/s0360-3016(02)02777-3","DOI":"10.1016\/S0360-3016(02)02777-3"},{"key":"2026071211422145348_j_raon-2023-0050_ref_012","doi-asserted-by":"crossref","unstructured":"Osborn J. Is VMAT beneficial for patients undergoing radiotherapy to the head and neck? Radiography 2017; 23: 73\u20136. doi: 10.1016\/j.radi.2016.08.008","DOI":"10.1016\/j.radi.2016.08.008"},{"key":"2026071211422145348_j_raon-2023-0050_ref_013","unstructured":"Adler JR, Cox RS. Preliminary experience with CyberKnife - Radiosurgery. Basel: S. Karger; 1996. p. 112\u201338."},{"key":"2026071211422145348_j_raon-2023-0050_ref_014","doi-asserted-by":"crossref","unstructured":"Kurup G. CyberKnife: a new paradigm in radiotherapy. J Med Phys 2010; 35: 63\u20134. doi: 10.4103\/0971-6203.62194","DOI":"10.4103\/0971-6203.62194"},{"key":"2026071211422145348_j_raon-2023-0050_ref_015","doi-asserted-by":"crossref","unstructured":"Tak\u00e1csi-Nagy Z, Ferenczi \u00d6, Major T, Akiyama H, Fr\u00f6hlich G, Ferenc O, et al. Results of sole postoperative interstitial, high-dose-rate brachytherapy of T1-2 tongue tumours. Strahlenther Onkol 2022; 198: 812\u20139. doi: 10.1007\/s00066-022-01901-w","DOI":"10.1007\/s00066-022-01901-w"},{"key":"2026071211422145348_j_raon-2023-0050_ref_016","doi-asserted-by":"crossref","unstructured":"Santos M, Guinot JL, Tortajada M, Vendrell JB, L\u00f3pez C, La Rosa A, et al. Is perioperative brachytherapy effective in carcinoma of the tongue? J Contemp Brachytherapy 2022; 14: 23\u20138. doi: 10.5114\/jcb.2022.113425","DOI":"10.5114\/jcb.2022.113425"},{"key":"2026071211422145348_j_raon-2023-0050_ref_017","doi-asserted-by":"crossref","unstructured":"Erickson BA, Demanes DJ, Ibbott GS, Hayes JK, Hsu ICJ, Morris DE, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2011; 79: 641\u20139. doi: 10.1016\/j.ijrobp.2010.08.046","DOI":"10.1016\/j.ijrobp.2010.08.046"},{"key":"2026071211422145348_j_raon-2023-0050_ref_018","doi-asserted-by":"crossref","unstructured":"Yamazaki H, Yoshida K, Yoshioka Y, Shimizutani K, Furukawa S, Koizumi M, et al. High dose rate brachytherapy for oral cancer. J Radiat Res 2013; 54: 1\u201317. doi: 10.1093\/jrr\/rrs103","DOI":"10.1093\/jrr\/rrs103"},{"key":"2026071211422145348_j_raon-2023-0050_ref_019","unstructured":"Union for International Cancer Control, UICC. TNM classification of malignant tumours. 8th Edition. Brierley JD, Gospodarowicz MK, Wittekind C, editors. Wiley Blackwell; 2017."},{"key":"2026071211422145348_j_raon-2023-0050_ref_020","doi-asserted-by":"crossref","unstructured":"Baltas D, Kolotas C, Geramani K, Mould RF, Ioannidis G, Kekchidi M, et al. A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys 1998; 40: 515\u201324. doi: 10.1016\/s0360-3016(97)00732-3","DOI":"10.1016\/S0360-3016(97)00732-3"},{"key":"2026071211422145348_j_raon-2023-0050_ref_021","doi-asserted-by":"crossref","unstructured":"ICRU Report 83, Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2012; 188: 97\u20139. doi: 10.1007\/s00066-011-0015-x.","DOI":"10.1007\/s00066-011-0015-x"},{"key":"2026071211422145348_j_raon-2023-0050_ref_022","doi-asserted-by":"crossref","unstructured":"Major T, Fr\u00f6hlich G, \u00c1goston P, Polg\u00e1r Cs, Tak\u00e1csi-Nagy Z. The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry. Strahlenther Onkol 2022; 198: 93\u2013109. doi: 10.1007\/s00066-021-01867-1","DOI":"10.1007\/s00066-021-01867-1"},{"key":"2026071211422145348_j_raon-2023-0050_ref_023","doi-asserted-by":"crossref","unstructured":"Petera J, Sir\u00e1k I, Laco J, Ka\u0161aov\u00e1 L, Tu\u010dek L, Dole\u017ealov\u00e1 H, et al. High-dose-rate brachytherapy in early oral cancer with close or positive margins. Brachytherapy 2015; 14: 77\u201383. doi: 10.1016\/j.brachy.2014.08.050","DOI":"10.1016\/j.brachy.2014.08.050"},{"key":"2026071211422145348_j_raon-2023-0050_ref_024","unstructured":"NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines Version 2.2023, Head and neck cancers. [cited 2023 Apr 15]. Available at: www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1437"},{"key":"2026071211422145348_j_raon-2023-0050_ref_025","doi-asserted-by":"crossref","unstructured":"Sresty NVNM, Ramanjappa T, Raju AK, Muralidhar KR, Sudarshan G, et al. Acquisition of equal or better planning results with interstitial brachytherapy when compared with intensity-modulated radiotherapy in tongue cancers. Brachytherapy 2010; 9: 235\u20138. doi: 10.1016\/j.brachy.2009.05.006","DOI":"10.1016\/j.brachy.2009.05.006"},{"key":"2026071211422145348_j_raon-2023-0050_ref_026","doi-asserted-by":"crossref","unstructured":"Yoshida K, Takenaka T, Akiyama H, Yamazaki H, Yoshida M, Masui K, et al. Three-dimensional image-based high-dose-rate interstitial brachytherapy for mobile tongue cancer. J Radiat Res 2014; 55: 154\u201361. doi: 10.1093\/jrr\/rrt079","DOI":"10.1093\/jrr\/rrt079"},{"key":"2026071211422145348_j_raon-2023-0050_ref_027","doi-asserted-by":"crossref","unstructured":"Akiyama H, Peszny\u00e1k C, B\u00e9la D, Ferenczi \u00d6, Major T, Polg\u00e1r Cs, et al. Image guided high-dose-rate brachytherapy versus volumetric modulated arc therapy for head and neck cancer: a comparative analysis of dosimetry for target volume and organs at risk. Radiol Oncol 2018; 52: 461\u20137. doi: 10.2478\/raon-2018-0042","DOI":"10.2478\/raon-2018-0042"},{"key":"2026071211422145348_j_raon-2023-0050_ref_028","doi-asserted-by":"crossref","unstructured":"Kubota H, Miyawaki D, Mukumoto N, Ishihara T, Matsumura M, Hasegawa T, et al. Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma. Radiat Oncol 2021; 16: 1. doi: 10.1186\/s13014-020-01701-5","DOI":"10.1186\/s13014-020-01701-5"},{"key":"2026071211422145348_j_raon-2023-0050_ref_029","doi-asserted-by":"crossref","unstructured":"Peterson DE, Doerr W, Hovan A, Pinto A, Saunders D, Elting LS, et al. Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer 2010; 18: 1089\u201398. doi: 10.1007\/s00520-010-0898-6","DOI":"10.1007\/s00520-010-0898-6"},{"key":"2026071211422145348_j_raon-2023-0050_ref_030","doi-asserted-by":"crossref","unstructured":"Swain M, Ghosh-Laskar S. Stereotactic body radiotherapy (SBRT) for primary non-metastatic head and neck cancer: when less is enough. Oral Oncol 2021; 116: 105265. doi: 10.1016\/j.oraloncology.2021.105265","DOI":"10.1016\/j.oraloncology.2021.105265"},{"key":"2026071211422145348_j_raon-2023-0050_ref_031","unstructured":"J\u00e1nv\u00e1ry ZL, Ferenczi \u00d6, Tak\u00e1csi-Nagy Z, Bajcsay A, Polg\u00e1r Cs, et al. Application of CyberKnife stereotactic radiosurgery in the treatment of head and neck cancer. Magy Onkol 2018; 62: 180\u20135."},{"key":"2026071211422145348_j_raon-2023-0050_ref_032","doi-asserted-by":"crossref","unstructured":"Biau J, Thivat E, Millardet C, Saroul N, Pham-Dang N, Molnar I, et al. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. BMC Cancer 2020; 20: 730. doi: 10.1186\/s12885-020-07231-3","DOI":"10.1186\/s12885-020-07231-3"},{"key":"2026071211422145348_j_raon-2023-0050_ref_033","doi-asserted-by":"crossref","unstructured":"Kim MS, Malik NH, Chen H, Poon I, Husain Z, Eskander A, et al. Stereotactic radiotherapy as planned boost after definitive radiotherapy for head and neck cancers: Systematic review. Head and Neck 2022; 44: 770\u201382. doi: 10.1002\/hed.26948","DOI":"10.1002\/hed.26948"},{"key":"2026071211422145348_j_raon-2023-0050_ref_034","doi-asserted-by":"crossref","unstructured":"Zhang Y, Chiu T, Dubas J, Tian Z, Lee P, Gu X, et al. Benchmarking techniques for stereotactic body radiotherapy for early-stage glottic laryngeal cancer: LINAC-based non-coplanar VMAT vs. Cyberknife planning. Radiat Oncol 2019; 14: 193. doi: 10.1186\/s13014-019-1404-z","DOI":"10.1186\/s13014-019-1404-z"},{"key":"2026071211422145348_j_raon-2023-0050_ref_035","doi-asserted-by":"crossref","unstructured":"Owosho AA, Thor M, Oh JH, Riaz N, Tsai CJ, Rosenberg H, et al. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. J Craniomaxillofac Surg 2017; 45: 595\u2013600. doi: 10.1016\/j.jcms.2017.01.020","DOI":"10.1016\/j.jcms.2017.01.020"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2023-0050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:17:35Z","timestamp":1783898255000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2023-0050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,30]]},"published-print":{"date-parts":[[2023,12,1]]}},"alternative-id":["10.2478\/raon-2023-0050"],"URL":"https:\/\/doi.org\/10.2478\/raon-2023-0050","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}